Caeregen Therapeutics has recently received a significant boost in funding for their regenerative medicine clinical candidate, CTR-107 (Noregen™). The company was awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute.
This grant will play a crucial role in advancing the development of CTR-107, which aims to address retinal-related vision loss caused by inherited and age-related diseases. Specifically, the therapy is initially being developed for Familial Exudative Vitreoretinopathy (FEVR), a rare inherited disorder that affects the formation of retinal blood vessels.
Walter Capone, CEO of Caeregen Therapeutics, expressed his gratitude for the NIH grant and emphasized its significance in supporting the nonclinical development program of CTR-107. He also mentioned that this funding will help expedite their investigational new drug (IND) process.